Estimating the Global and Regional Burden of Streptococcus pneumoniae Meningitis in Children: Protocol for a Systematic Review and Meta-Analysis.

Estimating the Global and Regional Burden of Streptococcus pneumoniae Meningitis in Children: Protocol for a Systematic Review and Meta-Analysis.

Publication date: Jul 16, 2024

Streptococcus pneumoniae (Spn) has been a leading cause of bacterial meningitis in children. The most recent estimation of the global burden of Spn meningitis indicates a positive trajectory in eliminating Spn through the implementation of pneumococcal conjugate vaccines. However, continuous monitoring and assessment of the disease burden are necessary due to the evidence of serotype replacement, antibiotic resistance, and the impact of the recent COVID-19 pandemic. The aim of this systematic review is to provide an updated and focused assessment of the global and regional burden of Spn meningitis in children, which can guide policies and strategies to reduce the disease burden. Population-based studies published from January 1, 2000, to January 1, 2022, were preliminarily searched from the electronic databases PubMed, Embase, Global Health (CABI), and CINAHL Plus without any language restrictions. Studies were included if they reported the incidence, prevalence, mortality, or case-fatality ratio (CFR) for Spn meningitis in children aged 0-4 years; meningitis was confirmed by cerebrospinal fluid culture; the study period was a minimum of 1 year; the number of reported cases was at least 10; and the study had no methodological ambiguities. The article screening process follows the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines. Characteristics including study period, setting, World Health Organization region, income level, vaccination information, and participant data (age, number of cases, deaths, sequelae, and risk factors) will be extracted from the included studies. Search results will be updated and incorporated into our review prior to finalizing the extraction of data. Generalized linear mixed models meta-analysis will be performed to estimate the pooled incidence and CFR. We will further assess the risk of bias and heterogeneity, and will perform subgroup and sensitivity analyses to provide a meaningful interpretation of the current burden and literature for pneumococcal meningitis. Our preliminary search in December 2021 yielded 9295 articles. Out of 275 studies that were assessed with our eligibility criteria, 117 articles were included. Data extraction and analysis are expected to be complete by January 2025. We plan to publish the results from the full study, including an updated search in 2024, by March 2025. Given that the major burden of Spn meningitis affects children under the age of 5 years, this systematic review will provide a thorough understanding of the global burden of Spn meningitis in this vulnerable population over a span of 2 decades. Insights into incidence trends, geospatial distribution, risk factors, and sequelae will be valuable for stakeholders, policy makers, and the academic community. This information will aid in the ongoing monitoring of the disease and in enhancing targeted vaccine programs to further mitigate the impact of the disease on children worldwide. PROSPERO CRD42021293110; https://tinyurl. com/kc3j5k4m. DERR1-10. 2196/50678.

Open Access PDF

Concepts Keywords
Guide Child
Meningitis child health
Pneumoniae Child, Preschool
Cost of Illness
global burden
Global Health
global health
Humans
Incidence
Infant
Infant, Newborn
infection
infectious disease
IPC
meningitis
Meningitis, Pneumococcal
Meta-Analysis as Topic
pediatric meningitis
pneumococcal
pneumococcal meningits
Pneumococcal Vaccines
Pneumococcal Vaccines
pneumonia
sepsis
streptococcal meningitis
Streptococcus pneumoniae
Streptococcus pneumoniae
systematic review

Semantics

Type Source Name
disease MESH Streptococcus pneumoniae Meningitis
disease VO protocol
disease MESH bacterial meningitis
disease MESH meningitis
disease IDO antibiotic resistance
disease MESH COVID-19 pandemic
disease VO population
disease VO cerebrospinal fluid
disease IDO process
disease VO organization
disease VO vaccination
disease MESH sequelae
disease VO vaccine
drug DRUGBANK Coenzyme M
disease MESH Park12
disease MESH infectious disease
pathway REACTOME Infectious disease
disease MESH pneumonia
disease MESH sepsis
disease MESH infection
disease MESH morbidity
disease VO conjugate vaccine
disease VO immunization
disease VO pneumococcal conjugate vaccine 10 valent
disease IDO country
drug DRUGBANK Penciclovir
disease MESH pneumococcal infections
disease IDO facility
disease VO publication
disease IDO blood
disease IDO assay
disease IDO quality
disease IDO site
drug DRUGBANK Methionine
disease VO frequency
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK BK-MDA
drug DRUGBANK Huperzine B
disease VO report
drug DRUGBANK Cefotaxime
disease MESH Vaccine Preventable Diseases
disease MESH CNS disease

Original Article

(Visited 3 times, 1 visits today)